Statements (25)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
|
| gptkbp:alsoKnownAs |
gptkb:AB-CHMINACA
|
| gptkbp:canBe |
gptkb:recreational_drug
|
| gptkbp:CASNumber |
gptkb:175865-59-5
|
| gptkbp:chemicalClass |
gptkb:synthetic_cannabinoid
|
| gptkbp:effect |
gptkb:cannabinoid_receptor_agonist
|
| gptkbp:hasInChIKey |
QZJYJZFMFZVQDF-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C23H32N4O2
|
| gptkbp:hasSMILES |
CC(C)[C@@H](C(=O)N)NC(=O)C1=NN(C2=CC=CC=C21)CC3CCCCC3
|
| gptkbp:hasUNII |
6K3K1I0F0E
|
| http://www.w3.org/2000/01/rdf-schema#label |
175865-59-5
|
| gptkbp:IUPACName |
gptkb:N-[(1S)-1-(Aminocarbonyl)-2-methylpropyl]-1-(cyclohexylmethyl)-1H-indazole-3-carboxamide
|
| gptkbp:legalStatus |
controlled substance in some countries
Anlage II in Germany Class B in the United Kingdom Schedule I in the United States |
| gptkbp:molecularWeight |
396.53 g/mol
|
| gptkbp:PubChem_CID |
86272952
|
| gptkbp:riskFactor |
toxicity
psychoactive effects |
| gptkbp:routeOfAdministration |
oral
inhalation |
| gptkbp:bfsParent |
gptkb:valganciclovir
gptkb:Valcyte |
| gptkbp:bfsLayer |
8
|